{
  "abstract": "We read with interest Gisbert et al’s report of EXIT, a randomised controlled trial (RCT) withdrawing anti-TNF in patients with inflammatory bowel disease (IBD), while continuing immunomodulators.1",
  "authors": [
    {
      "affiliations": [
        "The Edinburgh IBD Unit, NHS Lothian, Edinburgh, UK",
        "Deanery of Molecular, Genetic & Population Health Sciences, University of Edinburgh Western General Hospital, Edinburgh, UK"
      ],
      "name": "Jonathan Blackwell"
    },
    {
      "affiliations": [
        "The Edinburgh IBD Unit, NHS Lothian, Edinburgh, UK"
      ],
      "name": "Nikolas Plevris"
    },
    {
      "affiliations": [
        "Department of Nutritional Sciences, King’s College London, London, UK"
      ],
      "name": "Aaron Bancil"
    },
    {
      "affiliations": [
        "Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Minato-ku, Tokyo, Japan"
      ],
      "name": "Taku Kobayashi"
    },
    {
      "affiliations": [
        "The Edinburgh IBD Unit, NHS Lothian, Edinburgh, UK"
      ],
      "name": "Shahida Din"
    }
  ],
  "title": "Withdrawal of antitumour necrosis factor in patients with inflammatory bowel disease in remission: a randomised placebo-controlled clinical trial of GETECCU",
  "uid": "6ce6fa8a-dd07-5d11-b065-bd2c367a42da"
}